Edwards Lifesciences Management
Management criteria checks 3/4
Edwards Lifesciences' CEO is Bernard Zovighian, appointed in May 2023, has a tenure of 1.5 years. total yearly compensation is $12.87M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 0.012% of the company’s shares, worth $5.03M. The average tenure of the management team and the board of directors is 5.2 years and 4.5 years respectively.
Key information
Bernard Zovighian
Chief executive officer
US$12.9m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.01% |
| Management average tenure | 5.2yrs |
| Board average tenure | 4.5yrs |
Recent management updates
Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11
Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$2b |
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$13m | US$973k | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$1b |
| Mar 31 2023 | n/a | n/a | US$1b |
| Dec 31 2022 | US$3m | US$642k | US$2b |
Compensation vs Market: Bernard's total compensation ($USD12.87M) is about average for companies of similar size in the US market ($USD12.67M).
Compensation vs Earnings: Bernard's compensation has increased by more than 20% in the past year.
CEO
Bernard Zovighian (56 yo)
1.5yrs
Tenure
US$12,869,020
Compensation
Mr. Bernard J. Zovighian serves as Chief Executive Officer and Director at Edwards Lifesciences Corp since May 11, 2023 and was its President at Edwards Lifesciences Corp since January 1, 2023 until May 11...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$12.87m | 0.012% $ 5.0m | |
| Corporate VP & CFO | 10.8yrs | US$5.95m | 0.046% $ 19.2m | |
| Corporate Vice President of Strategy & Corporate Development | 8.8yrs | US$4.29m | 0.035% $ 14.5m | |
| Corporate VP and Group President of TAVR & Surgical Structural Heart | 1.8yrs | US$5.40m | 0.030% $ 12.6m | |
| Principal Accounting Officer | less than a year | no data | 0.00030% $ 124.5k | |
| Corporate VP of Advanced Technology & Chief Scientific Officer | 5.8yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Corporate VP & General Counsel | 5.2yrs | no data | no data | |
| Corporate Vice President of Public Affairs | 11.4yrs | no data | no data | |
| Corporate Vice President of Human Resources | 12.3yrs | no data | no data | |
| Senior Vice President of Quality & Regulatory Compliance | 1.3yrs | no data | no data | |
| GM & Senior VP of Surgical Structural Heart | 1.3yrs | no data | 0.00021% $ 87.2k |
5.2yrs
Average Tenure
58yo
Average Age
Experienced Management: EW's management team is seasoned and experienced (5.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$12.87m | 0.012% $ 5.0m | |
| Independent Director | 9.8yrs | US$335.06k | 0.012% $ 5.1m | |
| Independent Director | 4.3yrs | US$329.97k | 0.0013% $ 543.8k | |
| Independent Director | 8.7yrs | US$335.06k | 0.012% $ 5.0m | |
| Independent Director | 8.3yrs | US$356.42k | 0.0046% $ 1.9m | |
| Independent Chairman | 10yrs | US$347.97k | 0.012% $ 4.8m | |
| Independent Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 4.5yrs | US$334.97k | 0.0019% $ 776.2k |
4.5yrs
Average Tenure
64yo
Average Age
Experienced Board: EW's board of directors are considered experienced (4.5 years average tenure).